Media headlines about Chimerix (NASDAQ:CMRX) have trended somewhat positive this week, according to Accern Sentiment. The research firm identifies positive and negative press coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Chimerix earned a coverage optimism score of 0.22 on Accern’s scale. Accern also assigned news stories about the biopharmaceutical company an impact score of 46.99244653769 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
A number of brokerages recently commented on CMRX. JPMorgan Chase & Co. lowered Chimerix from a “neutral” rating to an “underweight” rating in a research report on Wednesday. HC Wainwright began coverage on Chimerix in a research report on Friday, February 2nd. They issued a “buy” rating and a $10.00 price objective on the stock. Zacks Investment Research lowered Chimerix from a “hold” rating to a “sell” rating in a research report on Monday, January 22nd. Finally, ValuEngine lowered Chimerix from a “sell” rating to a “strong sell” rating in a research report on Thursday, November 9th. Three equities research analysts have rated the stock with a sell rating, two have given a hold rating and one has issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average target price of $7.06.
Chimerix (CMRX) traded up $0.05 during midday trading on Wednesday, reaching $4.93. The company had a trading volume of 184,900 shares, compared to its average volume of 263,190. Chimerix has a 1 year low of $4.17 and a 1 year high of $6.64. The firm has a market cap of $229.98, a P/E ratio of -3.45 and a beta of 1.42.
In related news, insider Linda M. Richardson sold 19,833 shares of the stock in a transaction on Friday, December 1st. The stock was sold at an average price of $4.47, for a total value of $88,653.51. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 4.40% of the stock is currently owned by corporate insiders.
TRADEMARK VIOLATION WARNING: “Chimerix (NASDAQ:CMRX) Receiving Somewhat Favorable Media Coverage, Report Finds” was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece on another site, it was illegally copied and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this piece can be read at https://www.dispatchtribunal.com/2018/02/14/somewhat-favorable-media-coverage-somewhat-unlikely-to-affect-chimerix-cmrx-share-price.html.
Chimerix, Inc is a biotechnology company. The Company is focused on discovering, developing and commercializing medicines that address unmet medical needs. Its lead compound, brincidofovir, is in development as an oral and intravenous (IV) formulation for the prevention and treatment of deoxyribonucleic acid (DNA) viruses, including smallpox, adenoviruses (AdV), and the human herpesviruses.
Receive News & Ratings for Chimerix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix and related companies with MarketBeat.com's FREE daily email newsletter.